Roche Diagnostics AmpliChip CYP450 microarray will have to overcome several regulatory obstacles before it can gain market approval from the US Food and Drug Administration....Subscribers: click headline for more
Future of Roche Dx’s Five Remaining ASRs Unclear
Roche Diagnostics’ forced decision two weeks ago not to sell its AmpliChip CYP450 microarray as an analyte-specific reagent leaves in limbo the fate of five additional chips the Swiss company is to co-develop with Affymetrix.
Genaissance Pharmaceuticals, a pioneer in using haplotype technologies to draw drug-discovery alliances with some of the biggest names in pharma, now has its sights on a new market...Subscribers: click headline for more
The decision by Tepnel Life Sciences to buy Orchid Biosciences diagnostics division will give Orchid a much-needed cash infusion and may close the final chapter in the company s transition from a SNP-genotyping and molecular-diagnostics firm into a forensics and paternity-testing shop...Subscribers: click headline for more
Fulfilling a promise it made to industry this spring, the US Food and Drug Administration this week released for public comment its much-anticipated draft guidance on the submission of certain pharmacogenomics data...Subscribers: click headline for more